Ismail Mitha

5.9k total citations · 1 hit paper
12 papers, 1.4k citations indexed

About

Ismail Mitha is a scholar working on Epidemiology, Molecular Biology and Pharmacology. According to data from OpenAlex, Ismail Mitha has authored 12 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Epidemiology, 4 papers in Molecular Biology and 4 papers in Pharmacology. Recurrent topics in Ismail Mitha's work include Pneumonia and Respiratory Infections (4 papers), Diabetes Treatment and Management (4 papers) and Metabolism, Diabetes, and Cancer (4 papers). Ismail Mitha is often cited by papers focused on Pneumonia and Respiratory Infections (4 papers), Diabetes Treatment and Management (4 papers) and Metabolism, Diabetes, and Cancer (4 papers). Ismail Mitha collaborates with scholars based in Denmark, United Kingdom and Romania. Ismail Mitha's co-authors include Tsvetalina Tankova, Michael A. Nauck, Maria Düring, Kjeld Hermansen, Anders Frid, David R. Matthews, Nalini S. Shah, Milan Zdravković, David Matthews and Anne Bloch Thomsen and has published in prestigious journals such as New England Journal of Medicine, Diabetes Care and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Ismail Mitha

12 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes

2008 939 citations Michael A. Nauck, Anders Frid et al. Diabetes Care profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ismail Mitha Denmark	10	997	589	388	362	230	12	1.4k
John Pullman United States	13	441 0.4×	248 0.4×	228 0.6×	203 0.6×	232 1.0×	24	1.0k
Brenda Cirincione United States	17	378 0.4×	203 0.3×	508 1.3×	189 0.5×	160 0.7×	32	1.1k
Juan Camilo Arjona Ferreira United States	21	766 0.8×	335 0.6×	560 1.4×	425 1.2×	277 1.2×	53	2.1k
Goutam C. Mistry United States	15	287 0.3×	147 0.2×	346 0.9×	98 0.3×	197 0.9×	21	939
Hassan Gandjini France	10	125 0.1×	141 0.2×	374 1.0×	180 0.5×	356 1.5×	14	1.1k
Shuchean Chien United States	12	239 0.2×	169 0.3×	455 1.2×	191 0.5×	305 1.3×	14	896
April Barbour United States	14	123 0.1×	128 0.2×	259 0.7×	129 0.4×	103 0.4×	30	700
Steven C. Boike United States	16	143 0.1×	89 0.2×	307 0.8×	101 0.3×	153 0.7×	36	934
Gregory A. Winchell United States	15	223 0.2×	103 0.2×	224 0.6×	82 0.2×	354 1.5×	32	1.1k
Marina Basina United States	17	698 0.7×	82 0.1×	78 0.2×	358 1.0×	114 0.5×	54	1.2k

Countries citing papers authored by Ismail Mitha

Since Specialization

Citations

This map shows the geographic impact of Ismail Mitha's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ismail Mitha with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ismail Mitha more than expected).

Fields of papers citing papers by Ismail Mitha

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ismail Mitha. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ismail Mitha. The network helps show where Ismail Mitha may publish in the future.

Co-authorship network of co-authors of Ismail Mitha

This figure shows the co-authorship network connecting the top 25 collaborators of Ismail Mitha. A scholar is included among the top collaborators of Ismail Mitha based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ismail Mitha. Ismail Mitha is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Popescu, Monica, Ismail Mitha, William Nseir, et al.. (2019). Omadacycline for Community-Acquired Bacterial Pneumonia. New England Journal of Medicine. 380(6). 517–527. 171 indexed citations

Popescu, Monica, Ismail Mitha, Andrzej Madej, et al.. (2017). A Phase 3 Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of IV to Oral Omadacycline to Moxifloxacin for the Treatment of Adult Subjects with CABP (The OPTIC Study). Open Forum Infectious Diseases. 4(suppl_1). S543–S544. 11 indexed citations

Giaquinto, Carlo, Kulkanya Chokephaibulkit, Marinella Della Negra, et al.. (2017). Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1. The Pediatric Infectious Disease Journal. 37(5). 459–465. 9 indexed citations

Oldach, David, Péter M. Szabó, Ismail Mitha, et al.. (2015). LATE-BREAKING ABSTRACT: Oral solithromycin has a favorable profile versus oral moxifloxacin for treatment of adult community-acquired pneumonia (CABP) in elderly patients and those with COPD or asthma. PA2655–PA2655. 1 indexed citations

Gropper, Savion, et al.. (2014). Ozenoxacin 1% Cream in the Treatment of Impetigo: A Multicenter, Randomized, Placebo- and Retapamulin-Controlled Clinical Trial. Future Microbiology. 9(9). 1013–1023. 32 indexed citations

Nauck, Michael A., Anders Frid, Kjeld Hermansen, et al.. (2012). Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD ‐2 study. Diabetes Obesity and Metabolism. 15(3). 204–212. 121 indexed citations

Madhi, Shabir A., et al.. (2011). Immunogenicity and Safety of an Investigational Fully Liquid Hexavalent Combination Vaccine Versus Licensed Combination Vaccines at 6, 10, and 14 Weeks of Age in Healthy South African Infants. The Pediatric Infectious Disease Journal. 30(4). e68–e74. 35 indexed citations

Vázquez, José Antonio, Lauren L. Patton, Joel B. Epstein, et al.. (2010). Randomized, Comparative, Double-Blind, Double-Dummy, Multicenter Trial of Miconazole Buccal Tablet and Clotrimazole Troches for the Treatment of Oropharyngeal Candidiasis: Study of Miconazole Lauriad^®Efficacy and Safety (SMiLES). HIV Clinical Trials. 11(4). 186–196. 34 indexed citations

Perng, Reury-Perng, Ismail Mitha, Li‐Wen Chang, et al.. (2010). Efficacy and Safety of Nemonoxacin versus Levofloxacin for Community-Acquired Pneumonia. Antimicrobial Agents and Chemotherapy. 54(10). 4098–4106. 55 indexed citations

10.

Frid, Anders, Michael A. Nauck, Kjeld Hermansen, et al.. (2008). Liraglutide, a Once-daily Human GLP-1 Analog, In Type 2 Diabetes Provides Similar Glycem1c Control with Reduced Body Weight Compared with Glimepiride when Added to Metformin.. Canadian Journal of Diabetes. 32(4). 329–329. 12 indexed citations

11.

Nauck, Michael A., Anders Frid, Kjeld Hermansen, et al.. (2008). Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes. Diabetes Care. 32(1). 84–90. 939 indexed citations breakdown →

12.

Frid, Anders, Michael A. Nauck, Tsvetalina Tankova, et al.. (2008). Liraglutide, a Once-daily Human GLP-1 Analog, In Type 2 Diabetes Provides Similar Glycemic Control with Reduced Body Weight Compared with Glimepiride when Added to Metformin.. Canadian Journal of Diabetes. 32(4). 329–329. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact